Last reviewed · How we verify
Peri-operative chemotherapy
Peri-operative chemotherapy administers cytotoxic chemotherapy drugs before and/or after surgical resection to eliminate micrometastatic disease and improve overall survival in cancer patients.
Peri-operative chemotherapy administers cytotoxic chemotherapy drugs before and/or after surgical resection to eliminate micrometastatic disease and improve overall survival in cancer patients. Used for Solid tumors amenable to surgical resection with neoadjuvant and/or adjuvant chemotherapy.
At a glance
| Generic name | Peri-operative chemotherapy |
|---|---|
| Also known as | XELOX |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Peri-operative chemotherapy is a treatment strategy that combines chemotherapy with surgery to treat solid tumors. Neoadjuvant chemotherapy (given before surgery) aims to shrink tumors and eliminate circulating tumor cells, while adjuvant chemotherapy (given after surgery) targets residual microscopic disease that may remain after surgical resection. This multimodal approach improves local control and systemic disease control.
Approved indications
- Solid tumors amenable to surgical resection with neoadjuvant and/or adjuvant chemotherapy
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Cardiotoxicity
- Nephrotoxicity
- Peripheral neuropathy
Key clinical trials
- LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA) (NA)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NA)
- Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors (NA)
- Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (PHASE2)
- Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) (PHASE2)
- Fluorescent Intra-operative Tumor Margin Examination (PHASE2)
- Operative vs Non Operative Management of Adhesive Capsulitis: A Comparative Review
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: